
US drug tariff risk limited for Indian pharma; Sun Pharma exposure in focus: Vishal Manchanda
According to Vishal Manchanda, Pharma Analyst, Systematix Group, potential US action on drug pricing is seen as focused on patented medicines, limiting direct impact on…








